The Glucocorticoid Low-dose Outcome in RheumatoId Arthritis Study

PHASE4CompletedINTERVENTIONAL
Enrollment

451

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions
RheumatoId Arthritis
Interventions
DRUG

Prednisolone

1 capsule containing a tablet of 5 mg prednisolone/ day

DRUG

Placebo

1 capsule containing a placebo tablet / day

Trial Locations (28)

Unknown

Charite, Berlin

Facharztpraxis, Magdeburg

Knappschaftsklinikum Saar, Püttlingen

University of Debrecen, Debrecen

University of Genova, Genova

Noordwest Ziekenhuis, Alkmaar

Meander, Amersfoort

VUmc, Amsterdam

Gelre, Apeldoorn

Groene Hart Ziekenhuis, Gouda

UMCG, Groningen

MCL, Leeuwarden

LUMC, Leiden

MC Zuiderzee, Lelystad

MUMC, Maastricht

Maasstad, Rotterdam

Antonius Ziekenhuis, Sneek

HAGA, The Hague

UMC Utrecht, Utrecht

VieCurie MC, Venlo

CHU Coimbra, Coimbra

Hospital de Egas Moniz, Lisbon

Hospital de Santa Maria, Lisbon

Instituto Portugues de Reumatologia, Lisbon

Hospital de Ponte Lima, Ponte de Lima

Carol Davila University of Medicine and Pharmacy, Bucharest

Carol Davila, Bucharest

NURCH, Bratislava

All Listed Sponsors
collaborator

European Commission

OTHER

lead

Amsterdam UMC, location VUmc

OTHER

NCT02585258 - The Glucocorticoid Low-dose Outcome in RheumatoId Arthritis Study | Biotech Hunter | Biotech Hunter